论文部分内容阅读
目的观察米非司酮治疗子宫肌瘤的临床效果。方法对65例确诊为子宫肌瘤患者进行药物治疗,口服米非司酮12.5 mg,每天1次,连服3个月为1个疗程。治疗前后均用彩色超声监测子宫及肌瘤大小,实验室查血尿常规、肝功能、卵泡刺激素(FSH)、黄体生成素(LH)、雌激素(E2)、孕酮(P)、泌乳素(PRL)、雄激素(T)。结果52例患者在治疗期间均出现闭经,痛经和下腹坠胀感消失,贫血得以纠正。子宫及子宫肌瘤体积均明显缩小,缩小率分别为26.85%和45.68%(P<0.01)。血FSH、LH、E2、P测定治疗后平均水平较用药前下降(P均<0.01),其中以E2和P下降最为显著。结论米非司酮治疗子宫肌瘤效果好,不良反应少,是一种理想的药物治疗方法。
Objective To observe the clinical effect of mifepristone in treating uterine fibroids. Methods 65 cases of patients diagnosed with uterine fibroids were treated with oral mifepristone 12.5 mg once daily for 3 months for 1 course of treatment. Before and after treatment, the size of uterus and fibroids were monitored by color sonography. Blood samples were collected from the laboratory for examination of hematuria, liver function, FSH, LH, E2, prolactin (PRL), Androgens (T). Results 52 cases of patients with amenorrhea during treatment, dysmenorrhea and abdominal distension disappeared, anemia can be corrected. Uterine and uterine fibroids volume were significantly reduced, the reduction rate was 26.85% and 45.68% (P <0.01). The mean level of serum FSH, LH, E2 and P after treatment was lower than before treatment (all P <0.01), and the decrease of E2 and P was the most significant. Conclusion Mifepristone treatment of uterine fibroids good effect, fewer adverse reactions, is an ideal drug treatment.